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a b s t r a c t
Background: Graft-versus host disease (GVHD) is a complication of stem cell transplantation associated with
signiﬁcant morbidity and mortality. Non-speciﬁc immune-suppression, the mainstay of treatment, may result
in immune-surveillance dysfunction and disease recurrence.
Methods: We created humanised mice model for chronic GVHD (cGVHD) by injecting cord blood (CB)-derived
human CD34+CD38−CD45RA− haematopoietic stem/progenitor cells (HSPCs) into hIL-6 transgenic NOD/
SCID/Il2rgKO (NSG) newborns, and compared GVHD progression with NSG newborns receiving CB CD34−
cells mimicking acute GVHD. We characterised human immune cell subsets, target organ inﬁltration, T-cell repertoire (TCR) and transcriptome in the humanised mice.
Findings: In cGVHD humanised mice, we found activation of T cells in the spleen, lung, liver, and skin, activation of
macrophages in lung and liver, and loss of appendages in skin, obstruction of bronchioles in lung and portal ﬁbrosis in liver recapitulating cGVHD. Acute GVHD humanised mice showed activation of T cells with skewed TCR repertoire without signiﬁcant macrophage activation.
Interpretation: Using humanised mouse models, we demonstrated distinct immune mechanisms contributing
acute and chronic GVHD. In cGVHD model, co-activation of human HSPC-derived macrophages and T cells educated in the recipient thymus contributed to delayed onset, multi-organ disease. In acute GVHD model, mature
human T cells contained in the graft resulted in rapid disease progression. These humanised mouse models
may facilitate future development of new molecular medicine targeting GVHD.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

Research in context
Evidence before this study
GVHD is an important complication of haematopoietic stem cell
transplantation. Mouse models and clinical experience suggested important roles of activated T cells both in acute and chronic GVHD.
⁎ Corresponding author at: 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa
230-0045, Japan
E-mail address: fumihiko.ishikawa@riken.jp (F. Ishikawa).

GWAS studies implicated IL-6 in pathogenesis of chronic GVHD and
anti-IL6R Ab has been reported to ameliorate disease status in patients
with chronic GVHD.
Added value of this study
We created a chronic GVHD humanised mouse model by
transplanting human HSPCs into hIL-6 TG NSG newborns. In this
model, activation of both human T cells and macrophages was associated with tissue damage in skin, lung, and liver. We also created acute

https://doi.org/10.1016/j.ebiom.2019.02.001
2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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GVHD humanised mice by transplanting mature human leukocyte and
myeloid cells to determine cellular and molecular distinction between
acute and chronic GVHD. Through the comparison, we found that
co-activation of ﬁbrotic/sclerotic changes associated with T lymphocytes and macrophages in affected organs and higher expression of
genes associated with TGF-β and SMAD signaling are characteristic of
chronic GVHD.
Implications of all the available evidence
Our study revealed an important role of IL-6 and subsequent macrophage/T cell co-activation in the development of chronic GVHD. The
preclinical humanised mouse model may serve as a beneﬁcial tool for
the investigation of chronic GVHD biology and new treatment strategy.
1. Introduction
Graft-versus host disease (GVHD) is characterised by an attack of
host organs by donor-derived lymphocytes, and remains as one of the
serious complications following haematopoietic stem/progenitor cell
transplantation (HSCT). GVHD is classiﬁed into acute (aGVHD) and
chronic (cGVHD) forms according to the time of disease onset. Recently,
distinct mechanisms of pathogenesis between these two forms of GVHD
have been reported [1–3]. Nevertheless, the pathophysiology of cGVHD
at a molecular level is not well-understood, and studies that directly
compared cGVHD with aGVHD using the same donor cell source are
few.
Allogeneic mouse models have been developed to investigate acute
and chronic GVHD [4–10]. These models supported clariﬁcation of the
critical roles of T cells as well as donor- and host-derived antigen presenting cells in GVHD. Furthermore, Lockridge et al. described cGVHD
in a bone marrow-liver-thymus (BLT) model of humanised NOD/SCID/
Il2rgKO (NSG) mice engrafted with human fetal thymic and liver tissue
under the renal capsule and injected with HSPCs [11]. Sonntag et al.
reported that two out of 15 NSG recipients of human CD34+
haematopoietic stem/progenitor cells (HSPCs) showed cGVHD-like
changes at 6–7 months post-transplantation [12]. While these xenotransplantation models are important milestones in the development
of humanised mouse models of in vivo cGVHD, they lacked appropriate
humanised microenvironment in the recipient mice. In particular, we
focused on human IL-6 signaling, since IL-6 gene polymorphism is associated with the development of cGVHD and anti-human IL-6 receptor
monoclonal antibody (Tocilizumab) has shown some beneﬁt in
steroid-refractory cGVHD patients [13,14].
Here we present a humanised mouse model for cGVHD through
transplantation of human cord blood (CB)-derived HSPCs without implantation of human fetal tissues in human IL-6 expressing NSG mice
(hIL-6 Tg NSG). During long-term observation, these cGVHD humanised
mice showed cGVHD-like changes in multiple target organs including
skin, lung and liver. In addition, we created a humanised mouse
model for aGVHD by transplantation of human CB-derived CD34− mature blood and immune cells in NSG mice. Comparison of these two
humanised mouse models demonstrated the unique role of macrophages in cGVHD pathogenesis. Moreover, we identiﬁed differentially
expressed genes in human T cells associated with cGVHD and aGVHD
humanised mice. These ﬁndings suggest that treatment strategies directed against macrophages as well as speciﬁc target molecules associated with pathogenic T cells should be considered as a future therapy
for steroid-refractory GVHD.

2. Materials and methods
2.1. Human samples
CB samples were obtained from the Tokai and the Chubu Cord Blood
Bank under written informed consent. Peripheral blood (PB) samples
were obtained from patients with cGVHD and non-GVHD HSCT recipient at Toranomon Hospital under written informed consent. All experiments were performed with authorisation from the Institutional
Review Board for Human Research at RIKEN and were conducted according to the principles expressed in the Declaration of Helsinki.
2.2. Mice
Human IL-6 Transgenic NSG mice (hIL-6 Tg NSG) were generated by
pronuclear microinjection of BAC clone CTD-2594 N23 (GRCh37/hg19
chromosome7 22,724,723–22,964,038; BAC1), or RP11-692 K8
(GRCh37/hg19 chromosome7 22,320,340–22,505,348; BAC2) followed
by backcrossing of the transgene N5 generations using a markerassisted selection protocol from the original C57BL/6 strain onto NOD.
Cg-PrkdcscidIL2rgtm1Wjl (NSG) mice [15]. The copy numbers of the BAC
transgene were estimated by quantitative PCR of chloramphenicolresistance gene in a BAC vector using a mouse endogenous gene
(RAVER2) as an internal copy-number reference. All mice were bred
and maintained under SPF conditions at the animal facility of RIKEN
IMS according to guidelines established and approved by the Institutional Animal Committees at RIKEN.
2.3. Puriﬁcation and transplantation of human cord blood cells
Human CD34+ cells enriched using immune-magnetic beads
(130–046-703, Miltenyi Biotec) were used to isolate 7AAD−Lin−CD34+CD38− or 7AAD−Lin−CD34+CD38−CD45RA− human HSPCs using
FACSAria or FACSAria III (BD Biosciences). CB CD34− cells prepared by
immune-magnetic microbeads (130–050-1014, Miltenyi Biotec) were
used to isolate CB CD34−CD3+ cells using FACSAria. Non-Tg NSG and
hIL-6 Tg NSG newborns were sublethally irradiated at 150 cGy total
body irradiation using a 137Cs-source irradiator followed by intravenous
injection via the facial vein. To create cGVHD humanised mice,
1.7 × 103 to 4.5 × 104 HSPCs were transplanted. To create aGVHD
humanised mice, 105 to 106 CD34− or CD34−CD3+ cells were
transplanted. To create non-Tg NSG humanised mice, 7.2 × 103 to
4.2 × 105 HSPCs were transplanted. When recipients became moribund
(reduced activity or tachypnea), these mice were euthanised and
analysed. Non-Tg NSG humanised mice were euthanised concomitantly
as controls. Antibodies used for ﬂow cytometric analysis and cell sorting
are listed in Supplementary materials and methods.
2.4. RNA-seq analysis
Total RNA was extracted from human T cells and mouse
keratinocytes obtained from hIL-6 Tg NSG humanised mice (n = 5),
acute GVHD humanised mice (n = 2), non-Tg NSG humanised mice
(n = 2), and non-transplanted non-Tg NSG control mice (n = 3)
using Trizol (ThermoFisher Scientiﬁc). RNA sequencing data are deposited in the National Bioscience Database Center. RNA-seq libraries were
prepared using an NEBNext Ultra RNA Library Prep Kit for Illumina
(New England Biolabs) according to the manufacturer's protocol and
were sequenced using a HiSeq1500 DNA sequencer (Illumina single

Fig. 1. Reconstitution of human immunity in hIL-6 Tg NSG mice. (a) Representative ﬂow cytometry plots of a hIL-6 Tg NSG humanised mouse (IL6#1–1) demonstrating the engraftment of
human CD19+ B cells, CD33+ myeloid cells, CD3+ T cells, and CD56+ NK cells in BM and spleen. (b) Representative ﬂow cytometry plots showing splenic Treg subsets in a hIL-6 Tg NSG
humanised mouse (IL6#1–1). Foxp3+ Tregs are classiﬁed into CD45RA+Foxp3lo naïve Tregs (I), CD45RA−Foxp3hi effector Tregs (II), and CD45RA−Foxp3lo non-Tregs (III). (c) Frequency of
Foxp3+ Tregs in the spleen are lower in hIL-6 Tg NSG humanised mice (NSG: n = 11, IL-6: n = 14), with signiﬁcant reduction in naïve Tregs and effector Tregs (NSG: n = 11, IL-6: n = 7)
(*p = 0.0004, **p = 0.02, ***p = 0.03). Error bars represent mean ± SEM. (d) T cell-dominant engraftment was found in the skin of hIL-6 Tg NSG humanised mouse as shown by
representative ﬂow cytometry plot (IL6#1-1).
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read, 50 bp). The sequence reads were mapped to mouse genome (NCBI
version 37) or human genome (NCBI version 19) using TopHat2 (version 2.0.8) and bowtie2 (version 2.1.0) with default parameters and
gene annotation was provided by the NCBI RefSeq. The transcript abundances were estimated using Cufﬂinks (version 2.1.1). Cufﬂinks was run
with the same reference annotation with TopHat2 to generate FPKM
(fragments per kilobase per million mapped reads) values for known
gene models.
2.5. Transcription factor (TF) enrichment analysis
Enrichment analysis to evaluate effect of a TF on their binding target
genes was performed as described previously [16]. Brieﬂy, we compared the mean fold changes of gene expression of target genes of a
TF against that of the background (whole genes). To consider heterogeneous frequencies of TF binding among target genes, we used a
weighted t-test procedure into a parametric gene set enrichment analysis. The frequency of binding of a TF to their target genes was evaluated
based on the numerous high-throughput chromatin immunoprecipitation (ChIP) experiments obtained from the gene expression omnibus
database (GEO, www.ncbi.nlm.nih.gov/geo/). We used the weighted tstatistic as an enrichment score indicating the relative activity of a TF.
2.6. TCR sequencing
Total RNA was extracted from human T cells in hIL-6 Tg NSG
humanised mice and acute GVHD humanised mice using Trizol
(ThermoFisher Scientiﬁc). TCR-seq libraries were prepared using a
SMARTer Human TCR a/b Proﬁling Kit (Clontech Laboratories, Inc.) according to the manufacturer's protocols and were sequenced on a
Miseq DNA sequencer (Illumina). The human TCR repertoires were
analysed using MiXCR [17].
2.7. Measurement of human cytokine /chemokine levels
Plasma cytokine/chemokine levels in humanised mice and patient
samples were measured using the Bio-Plex system (Bio-Rad) with
Bio-Plex Human Cytokine 27-Plex and 21-Plex Assay kits (Bio-Rad).
2.8. Statistical analysis
The numerical data are presented as means ± SEM. Statistical
analyses (two-tailed t-tests and one-way ANOVA with Bonferroni
post-test) were performed using Microsoft Excel. The differences
were determined by two-tailed t-tests unless otherwise indicated. P
value b.05 was considered statistically signiﬁcant. Statistics for
Kaplan-Meier analysis were obtained using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user
interface for R (The R Foundation for Statistical Computing, Vienna,
Austria) [18].
3. Results
3.1. hIL-6 Tg NSG humanised mice transplanted with human HSPCs develop
cGVHD-like changes
We created human IL6 transgenic NSG mice (hIL-6 Tg NSG) by
microinjecting a bacterial artiﬁcial chromosome (BAC) containing the
human IL6 gene (clone: 2594 N23 or 692 K8) into C57BL/6 mice and

backcrossing onto the NSG background. The BAC transgene was stably
propagated in a Mendelian inheritance mode and their copy numbers
in mouse clones BAC3 and BAC32 were estimated to be 2.0 copies and
2.9 copies per haploid genome on average of triplicated measurements,
respectively. Plasma hIL-6 levels in hIL-6 Tg NSG mice were elevated at
baseline (IL-6, n = 2: IL-6#1 63.4 pg/ml, IL-6#2 60.7 pg/ml) while nontransgenic NSG mice showed background levels of human IL-6 in
plasma (NSG, n = 2: NSG#1 0.5 pg/ml, NSG#2 0.6 pg/ml).
To create cGVHD humanised mouse, we transplanted human CBderived HPSCs into sublethally-irradiated hIL-6 Tg NSG newborns. At
20 to 43 weeks post-transplantation, all hIL-6 Tg NSG humanised mice
developed signs of weakness including rufﬂed fur, anemia and reduced
mobility (n = 58). In 22 out of 58 these mice, we found macroscopic
skin lesions consistent with skin cGVHD. We examined human
immuno-haematopoietic reconstitution in 18 out of 22 and found
long-term multi-lineage engraftment of human CD19+ B cells, CD33+
myeloid cells, CD3+ T cells, and CD56+ natural killer cells in the bone
marrow (BM) and spleen of hIL-6 Tg NSG mice (Representative ﬂow cytometry plots shown in Fig. 1a, Table S1). Engrafted human T cells were
predominantly TCRαβ+ T cells. Interestingly, the frequency of Foxp3+
Tregs was lower in hIL-6 Tg NSG humanised mice (hIL-6 Tg, n = 14:
5.7 ± 0.9%, non-Tg NSG, n = 11: 10.5 ± 0.6%, p = .0004; Fig. 1b). Analysis of Foxp3+ Treg subsets CD45RA+Foxp3lo naïve Tregs (nTregs),
CD45RA−Foxp3hi effector Tregs (eTregs) and CD45RA−Foxp3lo nonTregs (non-Tregs) (Representative ﬂow cytometry plots in Fig. 1b)
[19] showed reduction of both naïve (p = 0.02) and effector (p =
0.03) fractions in the spleen of hIL-6 Tg NSG humanised mice (non-Tg
NSG, n = 11: nTregs 0.5 ± 0.1%, eTregs 3.9 ± 0.6%; IL-6, n = 7, nTregs
0.1 ± 0.04%, eTregs 1.8 ± 0.6%; Fig. 1c).
We performed histological examination of the skin, lung and liver in
hIL-6 NSG humanised mice with and without macroscopic skin lesions.
We found inﬁltration of human T cells in the macroscopically-apparent
skin lesions in all 14 mice examined (Representative ﬂow cytometry
plots shown in Fig. 1d). We performed histological examination of the
skin in 27 mice (with macroscopic skin lesions: n = 14; no macroscopic
skin lesions: n = 13). In 21 of 27, we found epidermal thickening, interface dermatitis (vacuolar changes beneath basal keratinocytes), reduced numbers of adipocytes, reduced numbers of hair follicles and
inﬁltration of human CD4+ and CD8+ T cells in epidermis and dermis
(Fig. 2a). These abnormalities were present even in 7 of 13 recipients
with no macroscopic skin lesions. In three out of 14, sclerotic changes
were present in the dermis. Altered expression of cytokeratins may trigger or exacerbate inﬂammatory skin diseases [20]. We found ectopic expression of cytokeratin 17 and reduced expression of cytokeratin 13 in
skin sections of hIL-6 Tg NSG humanised mice, suggesting possible
role of these cytoskeletal ﬁlaments in skin pathology [21,22] (Fig. S1).
In 19 of 27 examined, hIL-6 Tg NSG humanised mice lungs showed inﬁltration of human T cells in peri-vascular areas, obstruction of bronchioles, and peri-bronchiolar areas with ﬁbrotic changes (Fig. 2b). In 13
of 21 mice examined, we found reduction of cytokeratin 19-positive
small bile ducts in the liver and obstruction of portal triads presumably
as a consequence of chronic inﬂammation (Fig. 2c). These histopathological ﬁndings are consistent with cGVHD in skin, lung and liver of
mice with macroscopically normal skin as well as those with macroscopically appreciable skin lesions. Notably, cGVHD-like changes were
found in the majority of mice examined whether or not macroscopic
skin lesions were present. These changes were not found in non-Tg
NSG humanised mice and untransplanted NSG and hIL-6 Tg mice
(Fig. 2 and Fig. S2) [23].

Fig. 2. Histological analysis of cGVHD humanised mice. Histological analysis of (a) skin, (b) lung and (c) liver from hIL-6 Tg NSG humanised mice with a hIL-6 non-Tg NSG humanised
mouse as control. (a) H&E and immunohistochemical staining is consistent with interface dermatitis with epidermal thickening associated with inﬁltration of CD4+ and CD8+ T cells
in cGVHD humanised mice. White arrow shows sclerotic and thickened upper dermis (IL6#2-1). (b) Pulmonary sections of the same recipients show inﬁltration of CD4+ T and CD8+
T cells. (c) Inﬁltration of human CD45+ leucocytes including CD3+ T cells is detected in the liver of cGVHD humanised mice. In contrast, a non-Tg NSG humanised mouse (NSG#12-1)
shows normal skin, lung and liver histology. Scale bars: Low magniﬁcation 100 μm; high magniﬁcation 50 μm.
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3.2. Both cGVHD and aGVHD humanised mice show T cell activation
Although damage to host organs mediated by activated T cells is found
in both aGVHD and cGVHD, distinct mechanisms underlying the activation of donor T cells in these two clinical entities are not fully understood.
To evaluate the differences between aGVHD and cGVHD, we created an
aGVHD humanised mouse model by transplanting human CB-derived
CD34-negative mature haematopoietic cells (n = 16) or CD34−CD3+ T
cells (n = 10) into non-Tg NSG newborns (Table S2). CB-derived CD34negative cells contain T cells, B cells, myeloid cells and NK cells (CD34cells, n = 10: CD3+ cells 26.8 ± 3.6%; CD19+ cells 22.3 ± 5.4%; CD33+
cells 33.4 ± 5.9%; CD56+ cells 14.3 ± 3.4%, Fig. S3). Unlike hIL-6 Tg NSG
cGVHD humanised mice, onset of disease was rapid in aGVHD humanised
mice with 23 of 26 recipients becoming moribund within 73 days of
transplantation. Early onset of GVHD in these recipients led to reduced
survival compared with cGVHD humanised mice (Fig. 3a). Vast majority
of human CD45+ leukocytes in the PB, spleen, liver, lung, gastrointestinal
tract and skin of the aGVHD humanised mice were CD3+ T cells (Table S2
and Fig. S4a). Nine of 26 recipients developed macroscopically-apparent
skin lesions. Histological analysis of the skin showed epidermal thickening with human T cell inﬁltration and ectopic cytokeratin 17 expression
in the epidermis [21,22] (Fig. 3b, Fig. S1). Inﬁltration of human T cells
was also observed in the liver and small intestine, major target organs
of clinical aGVHD (Fig. S4a, Fig. 3b). Histologically, sclerotic changes and
reduction of bile ducts were absent in aGVHD humanised mice, in contrast to hIL-6 Tg NSG cGVHD humanised mice (Fig. 3b and Fig. S4b).
To understand the differences in mechanisms of immune-mediated
pathogenesis in cGVHD and aGVHD, we evaluated function of immune
cells in these two models. While the frequencies of CD4+ and CD8+ T
cells were similar in BM and spleen of cGVHD and aGVHD humanised
mice, frequencies of IFN-γ producing cells among splenic CD4+ T cells
(NSG, n = 11: CD4+IFN-γ+ 9.9 ± 2.1%; aGVHD n = 12: CD4+IFN-γ+
61.1 ± 5.0%; IL-6, n = 11: CD4+IFN-γ+ 25.7 ± 4.6%, p = 0.005 between
NSG and IL-6, p b 0.0001 between aGVHD and IL-6, and p b .0001 between NSG and aGVHD), and CD8+ T cells (NSG, n = 11: CD8+IFNγ+ 27.3 ± 4.7%; aGVHD, n = 12: CD8+IFN-γ+ 69.1 ± 4.9%; IL-6, n =
11: CD8+IFN-γ+ 41.4 ± 7.0%, p = 0.004 between aGVHD and IL-6
and p b 0.0001 between NSG and aGVHD) were higher in aGVHD
humanised mice (Fig. 3c–d, Fig. S5a). Frequencies of IL-17A producing
cells were similar among the three groups (NSG, n = 9: CD4+IL17A+
4.4 ± 1.3%; aGVHD, n = 12: CD4+IL17A+ 5.3 ± 1.2%; IL-6, n = 5:
CD4+IL17A+ 3.4 ± 1.2%, Fig. 3c, d). Mouse and human CD4+ T cells
that express speciﬁc chemokine receptors are known to produce speciﬁc sets of cytokines [24] [24]. Consistent with increased frequencies
of IFN-γ+CD4+ T cells, both aGVHD and hIL-6 Tg NSG cGVHD
humanised mice showed higher frequencies of CXCR3-expressing
human CD4+ T cells compared with non-Tg humanised mice while
the frequencies of CCR6-expressing human CD4+ T cells were similar
(Fig. S5b–d). Thus, although both acute and chronic GVHD showed T
cell activation, distinct histology, inﬁltrating immune cell subsets, and
the frequencies of IFN-γ production by activated T cells were observed
between acute and chronic GVHD model mice (Table S3).
3.3. Monocytes/macrophages are activated in the lung and liver of cGVHD
mice
Previously, certain cytokines and chemokines have been reported as
diagnostic and prognostic biomarkers of both acute and chronic GVHD

[25,26]. In cGVHD humanised mouse plasma, in addition to T cellassociated soluble factors (e.g., IFN-γ, IL-17A, IL-2Rα), myeloid cell- or
stromal cell-associated factors MIP-1β, IL-6, IL-12/23-p40, IL-18, IFNα2, and M-CSF[27,28] were elevated (Fig. 3e). Since human T cell reconstitution in PB of these mice were scant at 40 days post-transplantation
(Fig. S6a-b), macrophages activated by hIL-6 present at high levels likely
contributes to the production of these cytokines and chemokines. Consistent with these ﬁndings, plasma concentration of myeloid-associated
cytokines in cGVHD patients showed higher levels of macrophageassociated cytokines and chemokines MIP-1β, IL-18, M-CSF, and
IFN-α2 compared with a post-HSCT patient without GVHD, suggesting
macrophage activation may be one of the mechanisms contributing to
cGVHD pathogenesis (cGVHD patients, n = 3: MIP-1β 109.8 ±
14.2 pg/ml, IL-18121.3 ± 6.7 pg/ml, M-CSF 21.5 ± 0.8 pg/ml, IFN-α2
81.3 ± 14.1 pg/ml; patient with no GVHD, n = 1: MIP-1β 30.8 pg/ml,
IL-18 83.5 pg/ml, M-CSF below our-of-range, IFN-α2 15.6 pg/ml).
Next, we conﬁrmed in situ macrophage activation in cGVHD
humanised mice (Fig. 4). As shown in Fig. 4a, cGVHD mice showed sclerotic changes in the dermis, epidermal hyperkeratosis, reduction of adipocytes and appendages. On the other hand, intensive lymphocytic
inﬁltration into dermo-epidermal junction or appendages were characteristics of aGVHD mice. In the lung and liver of cGVHD humanised
mice, we detected prominent inﬁltration of CD68+ macrophages
(Fig. 4b–c and Fig. S6c–d). These CD68+ cells were larger in cGVHD
humanised mice compared with those in aGVHD humanised mice, suggesting that human macrophages were activated in cGVHD mice. In
cGVHD humanised mouse lungs, we also found inﬁltration of enlarged
macrophages in the peri-bronchiolar and peri-vascular areas with
obstructed bronchioles surrounded by both CD3+ T cells and CD68+
macrophages. In contrast, peri-bronchiolar and peri-vascular inﬁltration
in aGVHD humanised mice was CD3+ T cell-dominant, containing scant
macrophages (Fig. S7). Among 27 mice examined, 19 cGVHD mice
showed severe macrophage inﬁltration in the lung. In contrast, CD68+
cells in non-Tg NSG humanised mice and aGVHD humanised mice
were scant and did not appear to proliferate in the organ (Fig. 4b,
Fig. S7). Likewise, inﬁltration of enlarged macrophages in the portal
triad region was characteristic liver histopathology in cGVHD
humanised mice, in contrast to dominant T cell inﬁltration in the liver
of aGVHD humanised mice (Fig. 3b, Fig. 4c and Fig. S4b). Macrophage inﬁltration was also detected in the lung and liver of cGVHD humanised
mice without skin involvement, which might account for decreased activity and shortened survival (Fig. S8). Together, these ﬁndings in
cGVHD humanised mice suggest that co-activation of human macrophages and T cells may underlie pathogenesis of cGVHD while aGVHD
results from activated human T cells through recognition of host tissue
as non-self.
3.4. Gene expression signatures of human T cells and mouse keratinocytes
in acute and chronic GVHD humanised mice
Next, we examined the transcriptome of cGVHD and aGVHD
humanised mice to understand the distinct pathophysiology of acute
and chronic GVHD at the level of gene expression. To do so, we isolated
hCD45+CD3+ skin T cells, hCD45+CD3+TCRab+CD4+ spleen CD4+ T
cells, and hCD45+CD3+TCRab+CD8+ spleen CD8+ T cells from acute
and chronic GVHD humanised mice and non-Tg NSG humanised mice
(Fig. S9a-b). In addition, we isolated mCD45−hCD45−E-cadherin+
mouse skin keratinocytes from cGVHD humanised mice, aGVHD

Fig. 3. Comparison between hIL-6 Tg NSG cGVHD humanised mice and human aGVHD humanised mice. (a) Kaplan-Meier plot showing reduced survival of both cGVHD humanised mice
(n = 58, black) and aGVHD humanised mice (n = 26, red) compared with non-Tg NSG humanised mice (n = 15, blue) (cGVHD vs. non-Tg, p = 0.000225; aGVHD vs. non-Tg, p = 1.68
× 10−7; cGVHD vs. aGVHD, p = 2.11 × 10−22 by log-rank test). (b) Histological analyses of skin, liver and small intestine of an aGVHD humanised mouse (acute#A-1). Bars: (far left) 100
μm; (the others) 50 μm. (c) Representative ﬂow cytometry plots of a cGVHD humanised mouse (IL6#2-1). (d) Frequency of IFN-γ and IL-17A producing splenic T cells in non-Tg NSG
humanised mice (NSG-IFN-γ+, n = 11, NSG-IL-17A+, n = 9), aGVHD humanised mice (aGVHD: n = 12), and cGVHD humanised mice (IL6-IFN-γ+, n = 11, IL6-IL-17A+, n = 5). *P
= 0.005, **P = 0.004, ***P b 0.0001 by 1-way ANOVA with Bonferroni post-test. Error bars represent mean ± SEM. (e) Plasma cytokine/chemokine concentration of cGVHD
humanised mice (Black: IL-6, n = 8), aGVHD humanised mice (Red: aGVHD, n = 6) and non-Tg NSG humanised mice (Blue: NSG, n = 5).
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humanised mice, and non-transplanted control non-Tg NSG mice to analyse altered gene expression in mouse keratinocytes during the development of GVHD (Fig. S9a). When we compared gene expression
signatures of spleen T cells from aGVHD and cGVHD humanised mice
to those of non-Tg NSG humanised mice, 1121 and 1022 genes were
found to be differently expressed in aGVHD and cGVHD, respectively.
Among them, 470 genes were shared between aGVHD and cGVHD
mice (Fig. 5a). In aGVHD humanised mice, expression of VDR in skin T
cells and CCL4, TNFSF9, and BHLHE40 in spleen and skin T cells were upregulated compared with cGVHD humanised mice, reﬂecting activated
status of T cells.29–31 Among differentially-expressed genes, we found
higher expression of CCL3 in skin T cells of aGVHD humanised mice,
while CLU, a gene associated with macrophage activation, [32,33], was
upregulated in those of cGVHD humanised mice (Fig. 5b). Through transcription factor (TF) enrichment analysis that evaluates the effects of TFs
on gene expression [16], we identiﬁed signiﬁcantly higher expression of
target genes of multiple TFs in cGVHD humanised mouse skin T cells
(Fig. 5c, d). Among them were target genes of TRRAP, KAT2B, and
SRBP1 associated with phosphatidylinositol-3-kinase (PI3K) signaling
pathway [34–36]. In addition, we found enrichment of genes whose expression is potentially regulated by TFs CTBP1 and ZNF143 in cGVHD
humanised mouse skin T cells (Fig. 5d). These two TFs were reported
to be involved in epithelial-mesenchymal transition (EMT) [37,38].
EMT, triggered by aberrant TGF-β/SMAD signaling, is thought to contribute to the development of systemic sclerosis and bronchiolitis
obliterans after lung transplantation, both sharing pathological ﬁndings
with cGVHD [39,40]. Consistent with these ﬁndings, expression of target
genes of NR2C2 and KDM5A, associated with the TGF-β/SMAD signaling
pathway, were enriched in cGVHD humanised mouse skin T cells
[41–44] (Fig. 5d).
When comparing transcriptomic signatures of keratinocytes of
aGVHD humanised mice, cGVHD humanised mice and untransplanted
non-Tg NSG control mice (Fig. 5e-h), skin keratinocytes of cGVHD
humanised mice showed similarities with autoimmune diseases such
as type 1 diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosus (Fig. 5g). Higher expression of binding-target genes of Irf1,
Irf8 and Junb associated with activation of macrophages and chronic inﬂammation[45,46] was also conﬁrmed in keratinocytes of cGVHD mice
(Fig. 5h). We further evaluated mRNA expression of multiple organs including brain, salivary gland, liver, lung, spleen and skin (obtained from
the back, right leg and left leg) of a cGVHD humanised mouse by
quantitative PCR (Fig. S9c). In addition to genes downstream of IL-6 signaling, JAK2 and STAT3, several genes involved in production of inﬂammatory molecules such as IFNG, TGFB1, TNFSF10, and TLR2 and activation
markers for macrophages, MYD88 and NFκB1, were also upregulated.
From transcriptomic analyses, T cells of cGVHD humanised mice might
play pathogenic roles in not only cytotoxicity but also ﬁbrotic change
through accelerating TGF-β/SMAD signaling pathway, promoting EMT,
and macrophage activation.
3.5. TCR repertoire analyses of cGVHD and aGVHD humanised mice
We analysed the repertoire of alpha and beta loci of TCR genes (TRA
and TRB) in human T cells isolated from PB and spleen of aGVHD (n =
4) and cGVHD humanised mice (n = 3). While both possessed skewed
TRA and TRB repertoires in the skin and spleen, aGVHD mice appeared
to have more skewed repertoire (Fig. 6a). Therefore, we next examined
whether these expanded T cell clones are present among target organs
of aGVHD. From TRA and TRB repertoire analyses of CD4+ and CD8+ T
cells of an aGVHD humanised mouse, we found dominant clones were
shared among spleen, lung, and liver (Fig. 6b-c). These ﬁndings suggest

that aGVHD might be triggered by clonal expansion of speciﬁc T cell
clones that recognise host-derived common target antigens, and direct
cytotoxicity of expanded T cells may be the major cause of tissue
damage.
4. Discussion
In this study, we report the creation of cGVHD humanised mice
through engraftment of human HSPCs in hIL-6 Tg NSG recipients.
These humanised mice develop manifestations consistent with cGVHD
involving the skin, lung and liver, including interface dermatitis, peribronchiolar vasculitis, bronchiolitis obliterans and reduced numbers of
bile ducts associated with inﬁltration of human T cells and macrophages
in the affected areas [23,47]. These ﬁndings were unique to cGVHD
humanised mice, as affected skin, lung and liver of aGVHD humanised
mice showed predominantly T cell inﬁltration.
Several cGVHD mouse models have been reported to date [4–12].
Unlike these models, in our humanised mouse model, cGVHD was induced de novo through in vivo development of pathologic immune
cells from human CD34+CD38− or CD34+CD38−CD45RA− HSPCs in recipient mice that overexpress human IL-6. IL-6 has been implicated in
the pathogenesis of post-transplant cGVHD through studies showing
the association of IL-6 gene polymorphism with the development of
cGVHD [13] and Drobyski et al. reported the beneﬁcial effect of antihuman IL-6 receptor monoclonal antibody (Tocilizumab) in steroidrefractory cGVHD [14]. To directly compare acute and chronic GVHD
arising from the same human haematopoietic source, we further created an aGVHD humanised mouse model by injecting human CB
CD34− mature haematopoietic cells into NSG newborns. In line with
previous aGVHD humanised mouse models created by injection of
human PB mononuclear cells 48–52, both CD4+ and CD8+ T cells
were detected in the target organs of aGVHD.
In both cGVHD and aGVHD humanised mice, predominantly
CD45RA+CD45RO− naïve CB T cells became strongly activated in vivo
as shown by the elevation of plasma cytokine/chemokines such as IL2Rα, IFN-γ, and MIP-1β. Although activation of T cells is a hallmark of
both aGVHD and cGVHD, our humanised mouse models demonstrated
distinct histopathology, cytokine/chemokine proﬁles and transcriptome
in cGVHD, showing that activated macrophages cooperate with T cells
in cGVHD pathogenesis. In line with this observation, clinical cGVHD
samples also showed elevation of cytokines/chemokines associated
with macrophage development and activation. In contrast to aGVHD
where dominant oligo-clonal T cells against shared epitopes were present in multiple target organs, interaction of activated macrophages and
T cells in the setting of excess IL-6 and reduced immune-regulatory
function may explain broader T cell repertoire in cGVHD.
Importance of innate immunity in triggering aberrant immune reaction has been reported through GWAS using 492 donor-recipient paired
samples from HLA-matched sibling HSCT recipients [53]. Macrophage
activation in involved organs and expression of CLU and binding target
genes of NR2C2, associated with macrophage activation/recruitment,
[32,33,41] by T cells inﬁltrating the affected skin suggest the role of T
cells in recruiting and activating macrophages in cGVHD. In addition
to changes at the transcript level, we found elevated production of
human IL-12p40, IL-18, M-CSF, IFN-α2 by monocytes/macrophages
that may facilitate pathogenesis in cGVHD humanised mice.
In particular, M-CSF and type-1 IFN promote differentiation and
maturation of macrophages and are reported to be associated with the
development of cGVHD [4,54]. Recently, macrophage activation by
M-CSF has been shown to contribute to the development and progression of cGVHD via TGF-β production, ﬁbroblast activation, excess

Fig. 4. Inﬁltration of human immune cells and histopathology characteristic of acute and chronic GVHD humanised mice. (a-c) Histological sections of cGVHD humanised mice (IL-6: n =
3), an aGVHD humanised mouse (acute: n = 1), and non-Tg NSG humanised mouse (NSG: n = 1). (a) HE and hCD3 stained sections of skin dermo-epidermal junction (top two panels)
and skin appendages (bottom two panels) are shown. (b) HE and CD68 stained sections of peri-bronchiolar (top two panels) and peri-vascular (bottom two panels) regions are shown.
(c) hCD45 and CD68 stained sections of portal triad (top two panels) and peri-central vein (bottom two panels) regions are shown.
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Fig. 5. Gene expression signatures of T cells and keratinocytes in cGVHD and aGVHD humanised mice. (a) Venn diagrams indicating differentially expressed genes in splenic T cells among
cGVHD and aGVHD humanised mice. (b) Differentially expressed genes among skin and spleen T cells in acute and chronic GVHD mice and non-Tg NSG humanised mice. (c) KEGG
pathway enrichment analysis and (d) transcription factor (TF) enrichment analysis of skin T cells. (e) Venn diagrams indicating differentially expressed genes in skin keratinocytes
from cGVHD and aGVHD humanised mice. (f) Dimensionality reduction plot using tSNE. (g) KEGG pathway enrichment analysis and (h) transcription factor (TF) enrichment analysis
of skin keratinocytes.

production of extracellular matrix and collagen, and subsequent tissue
ﬁbrosis. [2,4]. Consistent with this, inhibition of monocytes and macrophages by pirfenidone ameliorates established cGVHD in mice [6].
While TGF-β activation can lead to immune-suppression through promotion of Treg differentiation, IL-6 has been reported to moderate this
effect [55]. Therefore, concurrent elevation of TGF-β and IL-6, may

initiate pathologic changes in cGVHD possibly through macrophage activation. In addition, IL-6 has been shown to switch differentiation of
monocytes from dendritic cells to macrophages [56]. Therefore, aberrant expression of IL-6 might disrupt homeostasis of both T cells and
myeloid cells. Our ﬁndings using the cGVHD humanised mice suggest
there are bidirectional and synergistic interactions between activated
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T cells and activated macrophages in the setting of elevated IL-6 and
suppressed Treg-mediated immune-regulation leading to cGVHD
pathogenesis.
Identifying molecular targets against GVHD is critical to reduce
therapy-related mortality in stem cell transplantation. Using the
cGVHD and aGVHD humanised mice, we identiﬁed gene expression signatures deﬁning these conditions both systemically (in the spleen) and
locally (in the skin). In aGVHD, certain genes such as VDR, TNFSF9, and
BHLHE40 were upregulated reﬂecting T cell activation via TCR stimulation [29–31]. On the other hand, activated human T cells in cGVHD
humanised mice showed upregulation of PI3K signaling (TRRAP,
KAT2B, and SRBP1), EMT-associated transcripts (CTBP1 and ZNF143),
and TGF-β/SMAD signaling (NR2C2 and KDM5A). Since both TGF-β/
SMAD signaling and EMT is important in tissue remodeling, these pathways might play important roles in the development of ﬁbrotic lesions
in cGVHD and suggest that these pathways may be potential therapeutic targets.
Though recent studies suggested anti-thymocyte globulin as a prophylactic therapy to reduce the frequencies of cGVHD [57], suppression
of T cells is problematic in patients with malignancy [58]. While corticosteroids are well-established as ﬁrst line treatment, there are no widelyaccepted second line therapies for cGVHD [59]. In addition to the recent
attempt of adoptive Treg transfer or in vivo Treg expansion using lowdose IL-2 [60,61], co-inhibition of activated macrophages and T cells
might become a promising therapeutic strategy for cGVHD. The
humanised mouse model for cGVHD may serve as a pre-clinical model
to assess therapeutic effect against hyper-activated human immune
cells in multiple organs.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.02.001.
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